Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

S A Schey, P Fields, J B Bartlett, I A Clarke, G Ashan, R D Knight, M Streetly, A G Dalgleish

    Research output: Contribution to journalArticlepeer-review

    286 Citations (Scopus)

    Abstract

    To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma.
    Original languageEnglish
    Pages (from-to)3269-76
    Number of pages8
    JournalJournal of Clinical Oncology
    Volume22
    Issue number16
    DOIs
    Publication statusPublished - 2004

    Fingerprint

    Dive into the research topics of 'Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma'. Together they form a unique fingerprint.

    Cite this